Arcutis Biotherapeutics announced the enrollment of the last subject in the Phase 1b study evaluating ARQ-255, a topical suspension of ivarmacitinib, a potent and selective JAK1 inhibitor, for the treatment of alopecia areata. ARQ-255 has been specifically formulated with Arcutis’ proprietary 4D technology to deliver drug deep into the skin to the base of the hair follicle, the site of the inflammation that underlies alopecia areata. Results from the study are expected to be reported in the first half of 2025.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARQT:
- Arcutis announces results from INTEGUMENT-OLE study of roflumilast cream
- Arcutis Biotherapeutics (ARQT) Riding High on Psoriasis Treatment
- Arcutis Biotherapeutics initiated with a Buy at Jefferies
- Arcutis jumps after Mizuho highlights ‘robust’ weekly script growth
- Arcutis to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference